Brought to you by 
MacroGenics signs on Gilead as newest DART partner
07 Dec 2015
Executive Summary
Antibody therapeutics developer MacroGenics Inc. has granted Gilead Sciences Inc. rights to four preclinical programs based on its Dual-Affinity Re-Targeting (DART) bi-specific antibody-generating platform. The specific targets for the collaboration were not disclosed.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
MacroGenics signs on Gilead as newest DART partner
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice